JP2015509961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509961A5 JP2015509961A5 JP2014560086A JP2014560086A JP2015509961A5 JP 2015509961 A5 JP2015509961 A5 JP 2015509961A5 JP 2014560086 A JP2014560086 A JP 2014560086A JP 2014560086 A JP2014560086 A JP 2014560086A JP 2015509961 A5 JP2015509961 A5 JP 2015509961A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- replacement therapy
- gaucher disease
- enzyme replacement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 206010018048 Gaucher's disease Diseases 0.000 claims 8
- 108010017544 Glucosylceramidase Proteins 0.000 claims 8
- 102000004547 Glucosylceramidase Human genes 0.000 claims 8
- 238000002641 enzyme replacement therapy Methods 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 102100018083 GBA Human genes 0.000 claims 2
- 108010039650 imiglucerase Proteins 0.000 claims 2
- 229960002127 imiglucerase Drugs 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920000742 Cotton Polymers 0.000 claims 1
- 210000003462 Veins Anatomy 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
Claims (14)
- グルコセレブロシダーゼ酵素補充療法薬を含む、ＩＩＩ型ゴーシェ病に罹患する対象を治療するための医薬組成物であって、前記グルコセレブロシダーゼ酵素補充療法薬が、前記対象に２時間未満にわたり静脈内注入される、医薬組成物。
- グルコセレブロシダーゼ酵素補充療法薬は、９０分以内にわたって投与される、請求項１記載の医薬組成物。
- グルコセレブロシダーゼ酵素補充療法薬は、６０分以内にわたって投与される、請求項１記載の医薬組成物。
- 前記対象への２時間未満にわたる静脈内注入によって投与される第２のグルコセレブロシダーゼ酵素補充療法薬と組み合わせて投与される、請求項１記載の医薬組成物。
- 前記グルコセレブロシダーゼ酵素補充療法薬は、ベラグルセラーゼ、イミグルセラーゼ、およびｕｐｌｙｓｏ（商標）から成る群より選択される、請求項１記載の医薬組成物。
- 前記グルコセレブロシダーゼ酵素補充療法薬は、１５〜６０Ｕ／ｋｇの用量で投与される、請求項１記載の医薬組成物。
- グルコセレブロシダーゼ酵素補充療法を現在受けているかまたは以前受けたことがあるＩＩＩ型ゴーシェ病に罹患する対象を治療するための医薬組成物であって、ベラグルセラーゼを含み、前記対象が、ゴーシェ病のために現在受けているまたは以前に受けたことがある療法薬に対する抗体の産生の検査で陽性反応を示したことに基づいて選択される、医薬組成物。
- 前記対象が、ゴーシェ病のために現在受けているまたは以前に受けたことがある療法薬に対するＩｇＥ抗体の産生の検査で陽性反応を示す、請求項７記載の医薬組成物。
- 前記対象が、ゴーシェ病のために現在受けているまたは以前に受けたことがある療法薬に対するＩｇＭ抗体の産生の検査で陽性反応を示す、請求項７記載の医薬組成物。
- 前記対象が、ゴーシェ病のために現在受けているまたは以前に受けたことがある療法薬に対するＩｇＧ抗体の産生の検査で陽性反応を示す、請求項７記載の医薬組成物。
- 前記対象がゴーシェ病のために現在受けているまたは以前に受けたことがある療法薬が、イミグルセラーゼである、請求項７記載の医薬組成物。
- 前記対象がゴーシェ病のために現在受けているまたは以前に受けたことがある療法薬が、ｕｐｌｙｓｏ（商標）である、請求項７記載の医薬組成物。
- ベラグルセラーゼが、１５〜６０Ｕ／ｋｇの用量で投与される、請求項７記載の医薬組成物。
- 前記ベラグルセラーゼが、９０分以内にわたって静脈内注入により前記対象に投与される、請求項７記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606089P | 2012-03-02 | 2012-03-02 | |
| US61/606,089 | 2012-03-02 | ||
| PCT/US2013/028608 WO2013130963A1 (en) | 2012-03-02 | 2013-03-01 | Compositions and methods for treating type iii gaucher disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017150619A Division JP6475293B2 (ja) | 2012-03-02 | 2017-08-03 | Ｉｉｉ型ゴーシェ病を治療するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509961A JP2015509961A (ja) | 2015-04-02 |
| JP2015509961A5 true JP2015509961A5 (ja) | 2016-04-21 |
| JP6230160B2 JP6230160B2 (ja) | 2017-11-15 |
Family
ID=49083333
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014560086A Active JP6230160B2 (ja) | 2012-03-02 | 2013-03-01 | Ｉｉｉ型ゴーシェ病を治療するための組成物および方法 |
| JP2017150619A Active JP6475293B2 (ja) | 2012-03-02 | 2017-08-03 | Ｉｉｉ型ゴーシェ病を治療するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017150619A Active JP6475293B2 (ja) | 2012-03-02 | 2017-08-03 | Ｉｉｉ型ゴーシェ病を治療するための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9623090B2 (ja) |
| EP (1) | EP2863941B1 (ja) |
| JP (2) | JP6230160B2 (ja) |
| KR (2) | KR20140138850A (ja) |
| CN (1) | CN104519905A (ja) |
| AU (1) | AU2013225816B2 (ja) |
| CA (1) | CA2865614A1 (ja) |
| HK (2) | HK1207005A1 (ja) |
| MX (1) | MX361231B (ja) |
| WO (1) | WO2013130963A1 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101658357B1 (ko) | 2015-02-17 | 2016-09-21 | 한림대학교 산학협력단 | 레스베라트롤을 함유하는 ⅲ형 고셔병 치료용 약학 조성물 |
| EP3264092A1 (en) * | 2016-07-01 | 2018-01-03 | Centogene AG | Use of lyso-gb1 as druggable target |
| JP7216075B2 (ja) | 2017-08-24 | 2023-01-31 | サノフイ | 酸性スフィンゴミエリナーゼ欠損症患者における骨状態異常の処置 |
| US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| JP2021501135A (ja) * | 2017-10-26 | 2021-01-14 | シャイア ヒューマン ジェネティック セラピーズ インコーポレイテッド | グルコセレブロシダーゼ及びイソファゴミンを含む製剤 |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| EP3731749A4 (en) | 2017-12-31 | 2022-07-27 | Neuroenhancement Lab, LLC | NEURO-ACTIVATION SYSTEM AND METHOD FOR ENHANCING EMOTIONAL RESPONSE |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| CN113382683A (zh) | 2018-09-14 | 2021-09-10 | 纽罗因恒思蒙特实验有限责任公司 | 改善睡眠的系统和方法 |
| EP3917558A1 (en) * | 2019-02-01 | 2021-12-08 | Oxyrane UK Limited | Glucocerebrosidase polypeptides |
| KR102356047B1 (ko) * | 2019-07-26 | 2022-02-07 | 재단법인 아산사회복지재단 | 효소대체요법 치료 비반응성 고셔병 치료용 약학조성물 |
| EP4117628A4 (en) * | 2020-03-10 | 2024-04-10 | University of Cincinnati | MATERIALS AND METHODS FOR THE TREATMENT OF GAUCHER’S DISEASE |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5272066A (en) | 1986-03-07 | 1993-12-21 | Massachusetts Institute Of Technology | Synthetic method for enhancing glycoprotein stability |
| US4925796A (en) | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| AU2946289A (en) | 1987-12-23 | 1989-07-19 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Cloned dna for synthesizing unique glucocerebrosidase |
| ES2093642T3 (es) | 1988-12-23 | 1997-01-01 | Genzyme Corp | Celulas cho que producen gluco-cerebrosidasa re-combinante enzimaticamente activa. |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| JPH03503721A (ja) | 1988-12-23 | 1991-08-22 | ジェンザイム コーポレイション | 酵素的に活性な組換えグルコセレブロシダーゼ |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| CA2099876C (en) | 1991-01-21 | 2002-03-26 | Michael L. Hayes | Production of enzymatically active glucocerebrosidase from recombinant cells |
| US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5911983A (en) | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
| AU5743994A (en) | 1992-12-10 | 1994-07-04 | Enzon, Inc. | Glycolipid enzyme-polymer conjugates |
| WO1994014837A1 (en) | 1992-12-21 | 1994-07-07 | Enzon, Inc. | Purification of proteinaceous material |
| DE69521074T2 (de) | 1994-03-30 | 2001-09-13 | Takara Shuzo Co | Transglykosylierungsverfahren zur Herstellung eines Kohlenhydrats oder eines Glykokonjugates |
| JP3002113B2 (ja) | 1994-03-30 | 2000-01-24 | 寳酒造株式会社 | 糖質又は複合糖質の製造方法 |
| US5670132A (en) | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| AU693329B2 (en) | 1995-04-13 | 1998-06-25 | Corning Incorporated | Dispersion managed optical waveguide |
| US5929304A (en) | 1995-09-14 | 1999-07-27 | Croptech Development Corporation | Production of lysosomal enzymes in plant-based expression systems |
| JP2002504083A (ja) | 1996-03-05 | 2002-02-05 | オーケスト インコーポレイテッド | ヒアルロン酸および増殖因子による骨の増殖を促進する方法 |
| EP0912179B1 (en) | 1996-07-15 | 2006-04-12 | MacroZyme DNM B.V. | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| AU4424497A (en) | 1996-09-13 | 1998-04-02 | Transkaryotic Therapies, Inc. | Therapy for alpha-galactosidase a deficiency |
| IL155588A0 (en) | 2003-04-27 | 2003-11-23 | Metabogal Ltd | Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| JPH10273500A (ja) | 1997-03-03 | 1998-10-13 | Noguchi Inst | 複合糖ペプチド及びその製造法 |
| JPH10306099A (ja) | 1997-03-04 | 1998-11-17 | Noguchi Inst | 新規複合糖ペプチドおよびその製法 |
| TW542721B (en) | 1997-08-06 | 2003-07-21 | Melaleuca Inc | Dietary supplements containing natural ingredients |
| DE69835308T2 (de) | 1997-08-07 | 2007-08-09 | University Of Utah Research Foundation, Salt Lake City | Prodrugs und Konjugate von Selenoenthaltenden Verbindungen und ihre Verwendung |
| US5939279A (en) | 1997-09-18 | 1999-08-17 | The Board Of Trustees Of The University Of Arkansas | Inhibition of bacterial binding by high-mannose oligosaccharides |
| CA2316015A1 (en) | 1997-12-22 | 1999-07-01 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| GB9802249D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
| GB9807464D0 (en) | 1998-04-07 | 1998-06-10 | Pharming Bv | Purification of human acid µ-glucosidase |
| EP0976838A1 (en) | 1998-05-06 | 2000-02-02 | Rhone-Poulenc Nutrition Animale | Enzymes mixture |
| JPH11318441A (ja) | 1998-05-14 | 1999-11-24 | Nagase & Co Ltd | 超耐熱耐酸性アミロプルラナーゼ |
| KR19990086271A (ko) | 1998-05-27 | 1999-12-15 | 손경식 | 면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제 |
| KR20010052499A (ko) | 1998-06-05 | 2001-06-25 | 아방티 파르마 소시에테 아노님 | 베타-시크리타제형 활성을 지닌 폴리펩타이드 |
| ES2558160T3 (es) | 1998-12-09 | 2016-02-02 | Phyton Holdings, Llc | Glicoproteínas que tienen glicosilación de tipo humano |
| GB9909066D0 (en) | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| WO2000076480A2 (en) | 1999-06-11 | 2000-12-21 | Eli Lilly And Company | Pharmaceutical materials and methods for their preparation and use |
| ATE234626T1 (de) | 1999-07-26 | 2003-04-15 | Searle & Co | Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| US6770468B1 (en) | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
| AU2352201A (en) | 1999-12-30 | 2001-07-16 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
| WO2001097829A2 (en) | 2000-06-19 | 2001-12-27 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| CN1156702C (zh) * | 2001-07-11 | 2004-07-07 | 上海晶泰生物技术有限公司 | 采用标记链霉亲和素-生物素技术的蛋白质芯片 |
| US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
| ES2619353T3 (es) | 2003-01-31 | 2017-06-26 | Mount Sinai School Of Medicine Of New York University | Terapia de combinación para tratar trastornos de deficiencia de proteínas |
| US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| WO2006069246A2 (en) | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| ES2391657T3 (es) | 2006-02-07 | 2012-11-28 | Shire Human Genetic Therapies, Inc. | Composiciones estabilizadas de proteínas que tienen un resto tiol libre |
| ES2366059T3 (es) | 2006-03-17 | 2011-10-14 | Biomarin Pharmaceutical Inc. | Ensayos para la detección de anticuerpos anti-enzimas lisosómicas. |
| DE602007013648D1 (de) | 2006-05-24 | 2011-05-19 | Amicus Therapeutics Inc | Tartratsalz aus Isofagomin und Verwendungsverfahren dafür |
| JP5364362B2 (ja) | 2008-12-24 | 2013-12-11 | 株式会社城南製作所 | ワイヤドラム式のウインドウレギュレータ |
| RU2733466C2 (ru) * | 2009-07-28 | 2020-10-01 | Шайр Хьюман Дженетик Терапиз | Композиции и способы для лечения болезни гоше |
| WO2011107992A2 (en) | 2010-03-02 | 2011-09-09 | Protalix Ltd. | Multimeric forms of therapeutic proteins and uses thereof |
| US9453847B2 (en) | 2010-07-19 | 2016-09-27 | Shire Human Genetic Therapies, Inc. | Mannose receptor C type 1 (MRC1) codon optimized cell line and uses thereof |
-
2013
- 2013-03-01 KR KR1020147027956A patent/KR20140138850A/ko active Application Filing
- 2013-03-01 AU AU2013225816A patent/AU2013225816B2/en active Active
- 2013-03-01 JP JP2014560086A patent/JP6230160B2/ja active Active
- 2013-03-01 EP EP13755466.3A patent/EP2863941B1/en active Active
- 2013-03-01 MX MX2014010536A patent/MX361231B/es active IP Right Grant
- 2013-03-01 CA CA2865614A patent/CA2865614A1/en not_active Abandoned
- 2013-03-01 US US14/381,680 patent/US9623090B2/en active Active
- 2013-03-01 CN CN201380019869.4A patent/CN104519905A/zh active Pending
- 2013-03-01 WO PCT/US2013/028608 patent/WO2013130963A1/en active Application Filing
- 2013-03-01 KR KR1020197030355A patent/KR102096752B1/ko active IP Right Grant
-
2015
- 2015-08-11 HK HK15107782.0A patent/HK1207005A1/xx unknown
- 2015-10-14 HK HK15110023.3A patent/HK1209328A1/xx unknown
-
2017
- 2017-08-03 JP JP2017150619A patent/JP6475293B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509961A5 (ja) | ||
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| WO2015031698A8 (en) | Site-specific antibody conjugation methods and compositions | |
| NZ719520A (en) | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway | |
| JP2014528901A5 (ja) | ||
| UY30450A1 (es) | Aplicacinn de alta frecuencia de terapia con toxina botulenica | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| EP3682875A3 (en) | Methods of treating pediatric metabolic syndrome | |
| JP2013503165A5 (ja) | ||
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| PH12018501903A1 (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| WO2012010966A3 (en) | A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders | |
| NZ609201A (en) | Means and methods for treating dlbcl | |
| AU2016204185A1 (en) | Methods of administering beta7 integrin antagonists | |
| WO2012055967A3 (en) | Treating diabetes melitus using insulin injections administered with varying injection intervals | |
| WO2011094467A3 (en) | Methods of treating diabetes with dll4 antagonists | |
| WO2014058979A8 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| WO2015003122A3 (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
| MX358680B (es) | Usos de inmunoconjugados dirigidos a cd138. | |
| WO2015023553A3 (en) | Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules | |
| RU2015134422A (ru) | Применение левоцитиризина и монтелукаста при лечении васкулита | |
| HRP20230070T1 (hr) | Tasimelteon za liječenje smith-magenis sindroma | |
| EA201590191A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и фампридина | |
| GB201017889D0 (en) | A polymeric nanoparticle | |
| AU2012334804A8 (en) | Modulators of C3a receptors |